- Home
- OFS vs ZNTL Comparison
OFS vs ZNTL Comparison
Compare OFS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- ZNTL
- Stock Information
- Founded
- OFS 2001
- ZNTL 2014
- Country
- OFS United States
- ZNTL United States
- Employees
- OFS N/A
- ZNTL N/A
- Industry
- OFS Finance/Investors Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- OFS Finance
- ZNTL Health Care
- Exchange
- OFS Nasdaq
- ZNTL Nasdaq
- Market Cap
- OFS 120.2M
- ZNTL 105.8M
- IPO Year
- OFS 2012
- ZNTL 2020
- Fundamental
- Price
- OFS $8.56
- ZNTL $1.33
- Analyst Decision
- OFS
- ZNTL Buy
- Analyst Count
- OFS 0
- ZNTL 7
- Target Price
- OFS N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- OFS 66.5K
- ZNTL 1.4M
- Earning Date
- OFS 07-31-2025
- ZNTL 08-08-2025
- Dividend Yield
- OFS 15.85%
- ZNTL N/A
- EPS Growth
- OFS N/A
- ZNTL N/A
- EPS
- OFS 2.25
- ZNTL N/A
- Revenue
- OFS $44,026,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- OFS N/A
- ZNTL N/A
- Revenue Next Year
- OFS N/A
- ZNTL N/A
- P/E Ratio
- OFS $3.81
- ZNTL N/A
- Revenue Growth
- OFS N/A
- ZNTL N/A
- 52 Week Low
- OFS $7.75
- ZNTL $1.01
- 52 Week High
- OFS $9.80
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- OFS 45.54
- ZNTL 50.91
- Support Level
- OFS $8.42
- ZNTL $1.15
- Resistance Level
- OFS $8.69
- ZNTL $1.38
- Average True Range (ATR)
- OFS 0.26
- ZNTL 0.10
- MACD
- OFS -0.01
- ZNTL 0.01
- Stochastic Oscillator
- OFS 21.92
- ZNTL 75.00
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.